Industry support of CME down 17%

Share this article:
Total commercial support of accredited CME fell 17% to $856 million in 2009, according to ACCME's annual report—marking its second straight year of double-digit declines on a percentage basis.

For 2007, ACCME data showed commercial support increasing 1%. Sandwiched between 2008, when industry grants slid 14% to $1 billion, and a decade of sizable gains before it, 2007 proved to be the peak. The 2009 total also marks the first time since 2003 that industry funding dipped below $1 billion.

The number of physicians and non-physicians participating in CME stayed fairly flat in 2009, rising just 1% and 3%, respectively. The steady attendance figures—10.7 million doctors and 6.8 million non-physicians—proved to be a lone bright spot.

Total income reported by accredited providers fell 7.6% to $2.2 billion, while total expenses also decreased 11.9% to $1.7 billion. Providers actually faced higher fees and administrative work last year as they incorporated new transparency and measurement policies. The lower expenses could partly reflect attrition among ACCME-accredited providers: there are now 707 vs. 725 in 2008.

Both the number of certified CME activities and the number of hours of CME logged were also down in 2009, with activities declining 5.8% to 95,062 and hours plunging 10.4% to 689,768.

Industry grants, now accounting for 39% of total CME income vs. 56% in 2008, have taken a hit due to overall budget cuts by drug and device companies and the extreme scrutiny placed on industry-supported CME due to perceived bias.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...